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Summary
In this article, a short overview of the current clinical situation of colorectal cancer 
(CRC) personalised medicine is presented. CRC is a complex, heterogeneous disease 
that involves multiple signalling pathways and tumors that appear histologically iden-
tical, but may have different prognoses and different responses to treatment. Basically, 
the treatment for colorectal cancer varies by tumor location, stage at diagnosis, and 
patient’s general condition. Recent newer polychemotherapy protocols, along with the 
use of inhibitors of the vascular endothelial growth factor (VEGF) and the epidermal 
growth factor receptor (EGFR) pathways, have enhanced the therapeutic responses and 
potentially also the patient’s prognosis. These recent improvements in anticancer tre-
atments and patient outcome in CRC were followed by a series of biomarker studies 
attempting to refine prognosis and predict patients who are likely to derive the most 
benefit from treatment. Consequently, validated predictive and prognostic biomarkers 
offer potential for personalised therapy for CRC patients. Microsatellite instability (MSI), 
as well as clinical pathological factors in stage II and III colorectal cancer, may now be 
considered to be a robust prognostic biomarker in the adjuvant setting. On the other 
hand, KRAS mutation status should be taken up as a part of routine clinical practice, as 
a predictive marker for response to EGFR-targeted therapies. The treatment of CRC is 
expected to become more and more routinely based on identified CRC subtypes and 
on validated prognostic and predictive biomarkers relatively soon (within several years), 
which should offer patients better therapeutic outcomes with less side effects.
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As regards its incidence and mortality, colorectal cancer (CRC) is a rela-
tively common tumor (the third most common tumor) [1-3]. The colorectal 
cancer treatment strategy is still based on standard clinical and pathological 
parameters, where the assessment of the progression and spreading of the 
tumor and general conditions of the patient are given priority [4-7]. On the 
other hand, clinical observations indicate that this “equal” treatment strategy 
is not optimal because not all treated patients demonstrate analogous success. 
Its causes may lie both in patients’ genetic differences and in other molecular 
heterogeneity between histologically “identical” tumors in different patients. 
In addition, as a result of further accumulation of genetic changes (clonal 
evolution of tumor) the genetic profile of metastases in a particular patient 
may be different to the original primary tumor finding, which in turn may 
affect the outcome of treatment if it is based only on molecular characteristics 
of the primary tumor. All this indicates that, whenever possible, treatment 
should be individualized according to patient’s pharmacogenetic characte-
ristics and the finding with respect to the predictive genetic alterations in 
autologous tumor cells. Such individualized approach (personalized cancer 
medicine) may result in more rational, higher-quality and more effective tre-
atment with less adverse reactions. A genetic analysis and/or profile of both 
the patients and their tumors may provide information and/or parameters in 
connection with the pharmacodynamics, pharmacogenetics and sensitivity 
of tumor cells to potential oncological treatment modalities, which rationali-
zes the treatment strategy and the potential antitumor effect [6-12].
The pathogenesis of colorectal cancer is complex. The risk of occurrence 
and occurrence of colorectal cancer depends on the genetic characteristics of 
the individual (heritage and epigenetic changes), their diet, intestinal flora, 
and lifestyle. Colorectal cancer is hereditary in less than 5% of patients. For 
example, in patients with familial adenomatous polyposis, an adenomatous 
polyposis coli (APC) gene which act as a tumor suppresor gene is mutated 
and inherited. In case mismatch repair (MMR) genes are mutated and inheri-
ted, hereditary non-polyposis colorectal cancer (HNPCC) with microsatellite 
instability (the Lynch Syndrome) will occur, characterized by high genetic 
instability. Lynch syndrome follows an autosomal dominant inheritance 
pattern. People who have Lynch syndrome have a significantly increased 
risk of developoing colorectal cancer but also an increased risk of developing 
other types of cancers [6,7,13-18]. 
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In most patients with colorectal cancer (approximately 95%), the impact 
of heritage is not so high, so we refer to it as sporadic colorectal cancer. Most 
of these tumors derive from malignant altered adenoma; in addition to gene-
tic mutations, these tumors also demonstrate chromosome instability (with 
potential loss of tumor suppression genes). This is a so-called phenotype 
of chromosome instability (CIN) and microsatellite stability (MSS). Among 
the smaller patient population with sporadic tumors (approximately 15%), 
malignant alteration is caused by high microsatellite instability (MSI-high), 
as a result of epigenetic changes or remodulation, which most often result 
in DNA mismatch repair gene promoter region CpG island hypermethyla-
tion (CIMP, CpG Island Methylator Phenotype). These genes are silenced by 
hypermethylation of the promoter region. Patients suffering from this mole-
cular type of tumor predominantly have a tumor finding in the right colon. 
As these two “groups” of sporadic tumors have different molecular profiles, 
that is, mutated genes, number of mutations and cellular molecular activati-
on routes and mechanisms, we are, for the time being, able to identify at least 
two types of sporadic colorectal cancer. This difference is to a certain degree 
reflected in the prognosis and strategy of systemic adjuvant treatment. For 
example, stage II MSI-H patients have a better prognosis than CIN patients, 
and they seem to have no benefit from adjuvant treatment with 5-fluoroura-
cil (5-FU) [4-7,13-18].
Systemic chemotherapy treatment of metastatic colorectal cancer is based 
on chemotherapeutic agents 5-FU, irinotecan, and oxaliplatin. Various stu-
dies have investigated whether molecular differences between patients can 
predict response to standard chemotherapy drugs to facilitate a more per-
sonalized approach to chemotherapy. Analysis regarding the genes or their 
products that may be targeted by such cytostatics or may be involved in the 
metabolism of these cytostatics or in repairing the damage to (tumor) DNA 
molecule caused by these agents are not in routine use. This might be due to 
the low number of studies, conflicting results between the studies, but also 
in not having standardized accepted laboratory procedures. The molecular 
target of 5-FU is the thymidylate synthase (TS) enzyme. TS is an important 
part of the folate–homocysteine cycle and purine and pyrimidine synthesis. 
Tumors with low expression of TS are less proliferative and may therefore 
be associated with a better prognosis. The metabolism of 5-FU is mediated 
by thymidine phosphorylase and dihydropyrimidine dehydrogenase (DPD). 
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Several variants in DPD have been associated with toxicity and DPD defici-
ency can result in severe and even fatal 5-FU toxicity [4-7,19,20]. 
Irinotecan is a topoisomerase-1 (Topo1) inhibitor and Topo1 is overexpre-
ssed in 43–51% of colorectal cancers. A large randomized FOCUS trial 
showed that patients with high levels of Topo-1 expression had improved 
OS with first-line combination chemotherapy compared with patients with 
low or moderate Topo1 levels. Irinotecan is detoxified by the enzyme “UDP 
glucuronosyltransferase 1 family, polypeptide A1” (UGT1A1). There is no cu-
rrent evidence of any benefit or harm of modifying irinotecan regimes based 
on an individual patient’s UGT1A1 genotype [4-7,19,20]. 
The excision nuclease “Excision Repair Cross-Complementing 1” 
(ERCC1) is involved in the repair of platinum-induced DNA damage and 
early data suggest that there was an association between low ERCC1 expre-
ssion and oxaliplatin effectiveness in patients with metastatic colorectal can-
cer. Enzyme “glutathione S-transferase” (GST) is involved in the oxaliplatin 
detoxification, and again, the relevance of specific polymorphisms seems cli-
nicaly unclear [4-7,19,20].
On the other hand, predictive analysis is fortunately available for the mo-
noclonal antibodies cetuximab and panitumumab. These two monoclonal 
antibodies may have an antitumor effect because they inhibit agonist bin-
ding to the epidermal growth factor receptor (anti-EGFR treatment) on colo-
rectal cancer cells. Through this effect, these two monoclonal antibodies are 
able to inhibit the stimulation of tumor cells in case there are no activation 
mutations in downstream intracellular molecules of this activation pathway. 
The KRAS molecule is one of these downstream molecules in this molecular 
pathway. When KRAS gene is mutated, it stimulates this molecular pathway 
itself, irrespectively of the EGFR blockade. This is why the use of these mo-
noclonal antibodies is conditional upon determining the KRAS and NRAS 
mutational status in autologous tumor cells. These two monoclonal antibodi-
es can only be used in patients having non-mutated KRAS and NRAS genes. 
KRAS and NRAS testing is now part of routine clinical practice. The huma-
nized monoclonal antibody bevacizumab inhibits the activity of the vascular 
endothelial growth factor (VEGF) where we have no predictive parameter or 
marker [4-7,19,20].
In conclusion, the existence of molecularly different cancer subtypes with 
different prognoses and potentially different treatment strategies may be 
said to be confirmed in colorectal cancer. A finding of MSI can be now consi-
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dered to be a robust prognostic biomarker in the adjuvant setting, and KRAS 
and NRAS testing has been taken up as part of routine clinical practice as 
a predictive marker for response to EGFR-targeted therapies. Personalized 
medicine is making advances in colorectal cancer [6,7,20,21].
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Sažetak
Personalizirana medicina kolorektalnog raka: kratki pregled
U prikazanom radu dan je kratak pregled kliničke primjene personalizirane me-
dicine kolorektalnog raka. Dijagnoza kolorektalnog raka bazira se na patohistološkim 
karakteristikama, ali rezultati molekularnih istraživanja ukazuju da se radi o skupini he-
terogenih tumora, koji se razlikuju u patogenezi, molekularnim aberacijama, prognozi 
i odgovoru na primijenjeno liječenje. Strategija liječenja raka kolorektuma još uvijek 
se prvenstveno temelji na smještaju tumora i procjeni uznapredovalosti i proširenosti 
tumora te općem stanju bolesnika. Razmjerno noviji polikemoterapijski protokoli kao i 
uporaba inhibitora vaskularnog endotelijalnog faktora rasta i receptora za epidermalni 
faktor rasta poboljšali su liječenje, a moguće i prognozu bolesnika. Ta novija poboljša-
nja paralelno prate i klinička ispitivanja s ciljem određivanja potencijalnih prognostičkih 
i prediktivnih biomarkera. Posljedično, validirani biomarkeri pružaju mogućnost perso-
nalizirane medicine za bolesnike s kolorektalnim rakom. Mikrosatelitska nestabilnost 
zajedno s kliničko-patološkim faktorima u stadiju bolesti II i III smatra se valjanim pro-
gnostičkim biomarkerom u strategiji adjuvantnog liječenja bolesnika stadija bolesti II i 
III. Nadalje, KRAS mutacijski status je parametar koji se mora odrediti ako se planira 
primjena inhibitora protiv receptora za epidermalni faktor rasta. Za očekivati je da će 
se unutar nekoliko slijedećih godina liječenje bolesnika s kolorektalnim rakom sve više i 
više temeljiti na nalazu molekularnih subtipova raka i prema validiranim prognostičkim 
i prediktivnim parametrima, jer bi takav pristup trebao osigurati bolju terapijsku učinko-
vitost i manje nuspojava.
Ključne riječi: kolorektalni rak; biomarkeri; personalizirana medicina; kemoterapija; 
ciljana terapija. 
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